Clinical trials: Parkinson's Disease Psychosis
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease, Psychoses
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
- Trial name
- NCT00095810
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy, Schizophrenia
Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients
Brain cells communicate with each other by releasing chemicals called neurotransmitters. In order for brain cells to transfer information, one cell will release a neurotransmitter that will be recognized by a receptor located on…
- Trial name
- NCT00001320
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Parkinson Disease Psychosis
Hallucinations in Parkinson's Disease
Investigation on how robotically mediated sensorimotor stimulation induces and triggers presence hallucinations in different clinical groups of parkinsonian patients, and in aged-matched controls
- Trial name
- NCT04592965
- Testing
- Clinical and neuropsychological assessments, Induction of PH and associated bodily states, Resting-state fMRI acquisition
- Where
- 6 sites in Spain, Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Olaf Blanke
Parkinson Disease
Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease
OBJECTIVES: I. Determine the efficacy and tolerability of clozapine in ameliorating psychosis in patients with idiopathic Parkinson's disease (PD). II.
- Trial name
- NCT00004826
- Testing
- clozapine
- Volunteers
- 60 people
- Sponsor
- Memorial Hospital of Rhode Island
Parkinson Disease Psychosis
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease.
- Trial name
- AGB101 PDP (NCT05824728)
- Testing
- AGB101
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Parkinson Disease Psychosis
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
Parkinson's disease is often characterised by movement symptoms such as rigidity and bradykinesia, however, there are a number of non-motor symptoms that can have a significant impact on quality of life.
- Trial name
- SCRIPT (NCT03661125)
- Testing
- Saracatinib
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College London
Parkinson's Disease Psychosis
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00658567
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 123 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease, Parkinson Disease Psychosis
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
Parkinson's disease psychosis encompasses a range of symptoms, including minor phenomena, frank hallucinations, and delusions. Minor phenomena include passage hallucinations (fleeting sense of a person, animal or object passing…
- Conditions
- Parkinson Disease, Parkinson Disease Psychosis, Hallucinations, Delusion
- Trial name
- NCT05240339
- Testing
- Observation of minor phenomena
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Rochester
Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD)…
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- NCT07509125
- Testing
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
- Trial name
- NCT01174004
- Testing
- pimavanserin tartrate
- Where
- 63 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease
EMD 128130 for the Treatment of Parkinson's Disease
This study will evaluate the effects of an experimental drug called EMD 128130 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa.
- Trial name
- NCT00009048
- Testing
- EMD 128130, IV Levodopa
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease Psychosis
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and…
- Trial name
- NCT03152292
- Testing
- Real-world, non-interventional
- Where
- 69 sites in United States
- Volunteers
- 764 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
- Trial name
- NCT06068465
- Testing
- pimavanserin tartrate
- Where
- 60 sites in China
- Volunteers
- 248 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Parkinson Disease Psychosis
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
A study to evaluate the safety and tolerability of SEP-363856 in subjects with Parkinson's Disease Psychosis. This study is accepting male and female participants 55 years of age and older who have been diagnosed with Parkinson's…
- Trial name
- NCT02969369
- Testing
- SEP-363856
- Where
- 24 sites in United States
- Volunteers
- 39 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease
Psychiatric and Cognitive Manifestations of Parkinson's Disease
Parkinson's Disease (PD) is often thought of as affecting movement only. In fact, most patients also experience psychiatric and cognitive symptoms, sometimes from the disease itself, and sometimes as a side-effect of PD…
- Trial name
- NCT00360633
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson's Disease Psychosis
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
- Trial name
- NCT01518309
- Testing
- pimavanserin tartrate (ACP-103)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease Psychosis
Presence Hallucination in Parkinson's Disease
Investigation on how robotically mediated sensorimotor stimulation induces and triggers presence hallucinations in patients with Parkinson disease
- Trial name
- NCT04579887
- Testing
- Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations
- Where
- 4 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- Olaf Blanke